1032314-85-4

Basic information

• Product Name: BenzaMide, N-[4-Methyl-3-[[4-(6-Methyl-3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]-4-[(4-Methyl-1-piperazinyl)Methyl]-
• Synonyms: BenzaMide, N-[4-Methyl-3-[[4-(6-Methyl-3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]-4-[(4-Methyl-1-piperazinyl)Methyl]-;N-[4-methyl-3-[[4-(6-methylpyridin-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide
• CAS NO: 1032314-85-4
• Molecular Formula: C₃₀H₃₃N₇O
• Molecular Weight: 507.62932
• Mol File: 1032314-85-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BenzaMide, N-[4-Methyl-3-[[4-(6-Methyl-3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]-4-[(4-Methyl-1-piperazinyl)Methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzaMide, N-[4-Methyl-3-[[4-(6-Methyl-3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]-4-[(4-Methyl-1-piperazinyl)Methyl]-(1032314-85-4)
• EPA Substance Registry System: BenzaMide, N-[4-Methyl-3-[[4-(6-Methyl-3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]-4-[(4-Methyl-1-piperazinyl)Methyl]-(1032314-85-4)

Safety Data

• Hazardous Substances Data: 1032314-85-4(Hazardous Substances Data)

Upstream product

• 1032314-41-2 N-(2-methyl-5-aminophenyl)-4-(6-methyl-pyridyl)-2-pyrimidine-amine 
• 1451042-78-6 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-oxo-2-pyrimidinyl)amino]-phenyl]benzamide 
• 659742-21-9 (6-methylpyridin-3-yl)boronic acid 
• 1025717-41-2 2-(2-methyl-5-nitrophenylamino)pyrimidin-4-one 
• 99-55-8 2-methyl-5-nitroaniline 
• 1451042-77-5 2-(5-amino-2-methylphenylamino)pyrimidin-4-one 

Relevant articles and documents

INTERMEDIATES FOR A NOVEL PROCESS OF PREPARING IMATINIB AND RELATED TYROSINE KINASE INHIBITORS

4-Oxo-2-phenylaminopyrimidine derivatives as intermediates for synth of tyrosine kinase inhibitors, in particular imatinib and nilotinib.

METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS

This application describes a novel technology in drug discovery and drug-based imaging/detection: the wrapping technology. This technology is based on identified singularities in the structure of soluble proteins. In contrast with drug-design approaches based on standard structural considerations, the packing of a protein, or more precisely, its dehydron pattern, may be used as a selectivity filter to design small-molecule inhibitors. The wrapping technology described herein is a novel form of rational drug design for avoiding side effects in drug therapy and sharpening the inhibitory impact of drugs on the oncokinome.